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clinic. Further thorough evaluation is necessary for a better 
understanding of the risk-benefit balance of this new treat-
ment option for relapsing MS. In this review, we discuss the 
basic mechanism of action, key clinical results of clinical trials 
and the emerging indication of natalizumab in MS. 
 Copyright © 2008 S. Karger AG, Basel 
 Introduction 
 Under physiological conditions, entry of circulating 
immune-competent cells into the central nervous system 
(CNS) is very low and strictly controlled by the endothe-
lial blood-brain barrier (BBB). In contrast, in multiple 
sclerosis (MS) and in its animal model experimental au-
toimmune encephalomyelitis (EAE), circulating leuko-
cytes get access to the CNS, where they start the molecu-
lar events leading to inflammation, edema and demyelin-
ation, which provide the basis for the development of the 
disabling clinical picture of the disease. Interaction of 
circulating immune cells with the BBB is thus a critical 
step in the pathogenesis of EAE and MS.
 It is now well established that leukocyte recruitment 
from blood into tissue is regulated by the sequential in-
teraction of adhesion and signaling molecules on leuko-
cytes and endothelial cells lining the vascular wall  [1–3] . 
The multistep leukocyte-endothelial interaction starts 
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 Abstract 
 In 1992, it was shown that monoclonal antibodies blocking 
  4 -integrins prevent the development of experimental auto-
immune encephalomyelitis, an animal model for multiple 
sclerosis (MS). As   4  1 -integrin was demonstrated to medi-
ate the attachment of immune-competent cells to inflamed 
brain endothelium in experimental autoimmune encepha-
lomyelitis, the therapeutic effect was attributed to the inhi-
bition of immune cell extravasation and inflammation in the 
central nervous system. This novel therapeutic approach 
was rapidly and successfully translated into the clinic. The 
humanized anti-  4 -integrin antibody natalizumab demon-
strated an unequivocal therapeutic effect in preventing re-
lapses and slowing down the pace of neurological deteriora-
tion in patients with relapsing-remitting MS in phase II and 
phase III clinical trials. The occurrence of 3 cases of progres-
sive multifocal leukoencephalopathy in patients treated 
with natalizumab led to the voluntary withdrawal of the 
drug from the market. After a thorough safety evaluation of 
all patients receiving this drug in past and ongoing studies 
for MS and Crohn’s disease, natalizumab again obtained ap-
proval in the US and the European Community. A treatment 
targeting leukocyte trafficking in MS has now re-entered the 
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with an initial transient contact of the circulating leuko-
cyte with the vascular endothelium, generally mediated 
by adhesion molecules of the selectin family and their 
respective carbohydrate ligands, or alternatively by   4 -
integrins and their endothelial ligands, which slows down 
the leukocyte in the blood stream. After the initial tether, 
the leukocyte rolls along the vascular wall with greatly 
reduced velocity and is then exposed to chemotactic fac-
tors of the family of chemokines presented on the endo-
thelial surface. Chemokines bind to G-protein-coupled 
receptors expressed on the leukocyte surface. G-protein-
coupled receptors deliver a pertussis toxin-sensitive ‘in-
side-out signal’, activating heterodimeric adhesion mol-
ecules of the integrin family, which are constitutively ex-
pressed on the leukocyte surface in an inactive stage. 
Activated integrins display an increased avidity and me-
diate the firm adhesion of the leukocytes to the vascular 
endothelium by binding to their endothelial ligands of 
the immunoglobulin (Ig) superfamily. Firm adhesion is 
the prerequisite for subsequent leukocyte diapedesis 
across the endothelium into the tissue. Concerning the 
multistep extravasation of circulating leukocytes,   4 -in-
tegrins and their endothelial counterreceptors are unique, 
as they can exert two functions, namely initial rolling and 
firm arrest, depending on whether the integrins are in a 
low or high affinity state  [4, 5] .
  4 -Integrins 
  4 -Integrins belong to the large family of adhesion re-
ceptors of the integrin family, which mediate both cell-
extracellular matrix and cell-cell interactions  [6] . In ad-
dition to their adhesive function, these receptors act as 
cellular sensors and signaling molecules  [6] . All integrins 
are composed of noncovalently linked   - and   -chains. 
The   4 -integrin chain dimerizes with either   1 or   7 .   4  1 
is also known as very late antigen 4  [7] or CD49d/CD29, 
while   4  7 was originally described as lamina propria-as-
sociated molecule  [8] . The major endothelial ligand for 
  4  1 -integrin is vascular cell adhesion molecule (VCAM)-
1 ( fig. 1 ). VCAM-1 is upregulated on endothelial cells 
during inflammation.   4  7 binds to mucosal addressin 
cell adhesion molecule (MAdCAM)-1, which is constitu-
tively expressed on high endothelial venules in mucosa-
associated lymphatic tissue, such as in the mesenteric 
lymph nodes and Peyer’s patches. Both   4 -integrins can 
additionally bind the extracellular matrix protein fibro-
nectin ( fig. 1 ). In contrast to the fibronectin receptor 
  5  1 -integrin, which binds the RGD amino acid sequence 
of fibronectin,   4 -integrins interact with the LDV se-
quence on the connecting segment 1 (CS-1) of fibronec-
tin. Last but not least, it is important to stress that on ac-
tivated lymphocytes,   4  7 can also bind to VCAM-1 
( fig. 1 )  [9] . Additional reported ligands for   4  1 -integrins 
Leukocyte Leukocyte
?
?
?
Leukocyte
Rolling Firm adhesion/Extravasation
Endothelium
MAdCAM-1 MAdCAM-1 VCAM-1VCAM-1 Fibronectin (CS-1)
Basal membrane/
extracellular matrix
47 47
47
41 41
41
 Fig. 1.   4 -Integrins are unique. Circulating 
immune-competent cells can slow down 
in the blood stream by engaging the endo-
thelial   4 -integrin ligand MAdCAM-1 or 
VCAM-1 on the vascular endothelium un-
der the influence of physiological flow, 
leading to leukocyte rolling at reduced ve-
locity. Hereby,   4  7 interacts with the first 
Ig domain of MAdCAM-1, and   4  1 binds 
to the first Ig loop of VCAM-1. In addition, 
  4 -integrins mediate G-protein-depen-
dent adhesion strengthening of leukocytes 
to the vascular endothelium. G-protein-
mediated inside-out signals lead to a con-
formational change of integrins and prob-
ably to integrin clustering. On activated 
lymphocytes,   4  7 can mediate adhesion 
strengthening by binding to the first Ig 
loop of MAdCAM-1 and VCAM-1.   4  1 
can bind to the first and the fourth Ig do-
main of VCAM-1. Additionally, both   4  1 
and   4  7 bind to the CS-1 domain of fibro-
nectin, and therefore, can mediate leuko-
cyte binding to the extracellular matrix. 
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
ts
bi
bl
io
th
ek
 M
ed
izi
n 
Ba
se
l  
   
   
   
   
   
  
13
1.
15
2.
21
1.
61
 - 
10
/2
5/
20
17
 1
1:
01
:1
6 
AM
 Engelhardt /Kappos 
 
Neurodegenerative Dis 2008;5:16–2218
include the secreted highly acidic glycoprotein osteopon-
tin  [10] and the tight junction protein junctional adhe-
sion molecule B  [11] .
 Preclinical Studies on   4 -Integrin-Mediated CNS 
Pathology 
 The earliest evidence for   4 -integrin-mediated CNS 
pathology has come from studies in the animal model 
EAE in the rat  [12] . Yednock et al.  [12] searched for adhe-
sion molecules involved in the extravasation of circulat-
ing immune cells into the CNS during EAE. Using the 
Stamper-Woodruff frozen section adhesion assay  [13] , 
they could demonstrate that antibodies which blocked 
the   4 - or the   1 -integrin chain, but not other antibodies, 
interfered with T cell and monocyte binding to inflamed 
vessels in frozen sections of EAE brains and concluded 
that   4  1 mediates the binding of leukocytes to the in-
flamed BBB. This was further supported by their observa-
tion that anti-  4 -integrin antibodies inhibited the devel-
opment of EAE by preventing the accumulation of in-
flammatory cells in the CNS of the treated animals. 
Numerous subsequent studies confirmed and extended 
these original findings. Frozen section adhesion assays on 
EAE brains in mice demonstrated the binding of lympho-
cytes via both   4 -integrins, namely   4  1 and   4  7 , to the 
inflamed cerebral vessels via their respective endothelial 
ligand VCAM-1 in vitro  [14] .  Furthermore, adhesion but 
not the transendothelial migration of encephalitogenic T 
cells to brain endothelial cells in vitro was shown to be 
mediated via   4 /VCAM-1 interactions  [15–18] . Different 
antibodies blocking   4 -integrins were shown to inhibit 
the development of EAE and even reverse the ongoing 
disease by preventing inflammatory cells from crossing 
the BBB in EAE models in rats, mice and guinea pigs  [19–
21] . However, discordant effects of anti-  4 -integrin treat-
ment were also reported depending on the application be-
fore or after the onset of relapsing EAE  [22] ; no therapeu-
tic effect was seen if certain mouse strains were used in 
the EAE studies  [23] . On the other hand, antibodies block-
ing the endothelial   4 -integrin ligand VCAM-1 were 
again demonstrated to interfere with the development of 
EAE in a comparable fashion with blocking   4 -integrin 
 [24, 25] . Furthermore, it was recognized that encephalito-
genic T cells require expression of   4 -integrin to enter the 
CNS and cause EAE  [24] . Interestingly, although enceph-
alitogenic T cells were shown to express both   4  1 and 
  4  7 , neutralizing   4  7 antibodies did not inhibit EAE in 
SJL mice  [25] . In contrast,   7 -integrin-deficient mice ex-
hibited mild EAE  [26] , suggesting that the precise role of 
  4  7 -integrin in EAE pathogenesis and probably MS re-
mains to be clarified. Finally, although the CS-1-contain-
ing fibronectin isoform binds   4 -integrins, its potential 
involvement in EAE or MS has not been addressed in de-
tail  [27, 28] . This is important in the context of MS, where 
the expression of VCAM-1 by the cerebral vasculature re-
mains controversial. One study reported VCAM-1 ex-
pression on CNS venules during MS  [29] , whereas others 
did not confirm these findings  [30, 31] .
 More recent intravital microscopy studies were able to 
provide direct evidence for   4 -integrin-mediated leuko-
cyte interaction with the endothelial BBB in vivo. During 
EAE,   4 -integrins were shown to mediate leukocyte roll-
ing and G-protein-dependent arrest in pial venules  [32] . 
Interestingly, encephalitogenic T cells already use   4 -in-
tegrins to interact with the noninflamed BBB. Perform-
ing intravital microscopy of the spinal cord white matter 
in mice, it was shown that the interaction of encephalito-
genic T lymphoblasts with the noninflamed spinal cord 
microvasculature is unique as T cells do not roll and due 
to the predominant involvement of   4 -integrins in initial 
T cell capture and subsequent G-protein-dependent ad-
hesion strengthening  [33] . The endothelial ligand was 
identified as VCAM-1, which is constitutively expressed 
at low levels in CNS microvessels, at least in mice  [34] .
 At this point, we would like to stress that natalizumab 
binds the   4 -integrin chain irrespective of its associated 
  -chain and therefore blocks both   4  1 - and   4  7 -integ-
rins. In most publications, natalizumab is referred to as 
blocking   4  1 -integrin  [35, 36] . Although this statement 
is absolutely correct, it might still be misleading as na-
talizumab equally well binds   4  1 - and   4  7 -integrins 
and therefore probably exerts its therapeutic effects be-
cause it blocks   4 -integrins binding to their ligands in-
cluding both VCAM-1 and MAdCAM-1, which is re-
quired for leukocyte recruitment from blood into in-
flamed tissues.
 Therapeutic Effects of Natalizumab in MS 
 Based on the dominant role of   4 -integrins in leuko-
cyte migration across the BBB observed in EAE, this ap-
proach was translated into the clinic. A mouse monoclo-
nal antibody directed against the   4 -integrin chain was 
humanized and placed on the IgG4 framework and 
named natalizumab.
 Three trials were looking at magnetic resonance imag-
ing (MRI) outcomes only, and all demonstrated that na-
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talizumab was able to significantly lessen MRI activity 
compared with placebo alone  [37–40] . One of these phase 
II clinical trials also showed a promising reduction in the 
relapse rate by approximately 50% over 6 months in a 
group of MS patients with active relapsing and secondary 
progressive disease  [40] .
 Four randomized placebo-controlled trials studied 
both clinical and MRI outcomes. Two trials compared 
natalizumab with placebo  [40, 41] , one studied the com-
bination of natalizumab and IFN-  1a (Avonex) 30   g per 
week intramuscularly compared with IFN-  1a alone  [42] , 
and one phase II study analyzed natalizumab as an addi-
tion to ongoing glatiramer acetate treatment  [43] . In the 
large phase III trial against placebo, AFFIRM  [41] , pa-
tients had a mild disability and were entered quite early 
in their disease course [mean Expanded Disability Status 
Scale (EDSS) 2.3, median duration 5 years], whereas in 
the large phase III trial studying combination therapy, 
SENTINEL  [42] , patients were at a somewhat later stage, 
having already had breakthrough activity while on IFN-
  1a therapy (mean EDSS 2.4–2.5, median duration 7 
years). By contrast, in the phase II trial, which included 
both relapsing-remitting MS and secondary progressive 
MS patients  [39, 40] , the disability at baseline was consid-
erably greater (mean EDSS 4.2–4.4, mean duration 11.7 
years). All three of these natalizumab trials  [39–42] 
showed a significant benefit of treatment on both clinical 
and MRI measures of disease activity, with MRI activity 
being suppressed by 80–90% and relapse rates being re-
duced by 50–70%. In addition, in both of the two larger 
(and longer) trials  [41, 42] , there was a significant reduc-
tion in progression of impairment/disability (as mea-
sured by the EDSS or MS Functional Composite, as well 
as by quality of life scales). The effect size and the statisti-
cal significance for natalizumab with each of these out-
comes were generally larger than those reported using 
any of the other currently available therapies  [44–55] , es-
pecially with respect to the clinical outcomes.
 However, the real magnitude of any such improved ef-
ficacy is impossible to define accurately because there are 
no direct head-to-head trials. The cohorts studied in the 
respective pivotal trials are probably different, although 
many baseline characteristics were similar. The patient 
cohorts for the IFN-  and glatiramer pivotal trials were 
drawn a decade or more in the past (when disease-modi-
fying treatments were unavailable) and probably differ in 
their implicit disease characteristics from cohorts drawn 
at a time when it is standard practice to initiate disease-
modifying therapy at the time of confirmed relapsing-re-
mitting MS diagnosis. In all of these trials, the therapeu-
tic benefits of natalizumab seemed to be accompanied by 
very few notable side effects over the 2 years of therapy. 
Although many patients (in both the treatment and com-
parative arms in both of the phase III trials) experienced 
adverse events, there were few statistically meaningful 
differences between groups and very little consistency of 
any reported differences between trials  [41, 42] . Never-
theless, approximately 2–4% of patients had anaphylactic 
or other hypersensitivity reactions to natalizumab, and 
in approximately 1%, these were considered serious by 
the investigators  [41, 42] . Approximately 6% of patients 
developed persistent binding antibodies to natalizumab 
and, in these patients, the therapeutic effect of natali-
zumab seemed to be completely neutralized  [41, 42] .
 Therapeutic Risks of Targeting   4 -Integrins in MS 
 Nevertheless, despite the overall encouraging results, 
there are reasons for caution. After completion of the 
clinical trial, 2 patients in the SENTINEL trial (both in 
the arm receiving combined natalizumab and IFN-  1a 
therapy) developed progressive multifocal leukoenceph-
alopathy (PML) and one  of them died  [56, 57] . In review-
ing the previous experience with natalizumab in Crohn’s 
disease, a third case of PML was identified in a patient 
receiving natalizumab alone  [58] . However, this patient 
had previously been immunosuppressed with several 
agents (including natalizumab) and was still lymphope-
nic at the time natalizumab was restarted, prior to the 
development of PML. Consequently, the basis for this 
complication is not entirely clear. However, the possibil-
ity that concurrent immunosuppression (either from 
IFN-  or otherwise) contributes to the development of 
PML in patients on natalizumab cannot be excluded. Nor 
can we exclude the possibility that the risk is due to na-
talizumab alone and that this risk may increase with 
greater time on therapy. Although not definitely proven, 
it may be assumed that abrogated or at least significantly 
reduced immune surveillance in the CNS caused by in-
hibition of entry of activated immune cells leads to re-
duced suppression of the opportunistic JC virus. Other 
effects of natalizumab, as for example the increased re-
lease of hematopoietic progenitor cells from bone mar-
row, may have contributed to this complication  [59] .
 As extensive studies of stored serum samples failed to 
reveal viremia in 2 of the 3 patients prior to the onset of 
clinical symptoms of PML, and because imaging features 
of MS and PML overlap to some degree, it seems that cur-
rently, there are no laboratory tests or imaging proce-
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dures to reliably monitor patients for this potential com-
plication. However, it is possible to monitor a patient’s 
specific cellular immunity to the JC virus and, perhaps, 
such a strategy could be developed into a valid commer-
cial test in the future.
 In clinical practice, neurologists face the difficult chal-
lenge of accurately assessing both the risks and the ben-
efits of therapy. Yousry et al.  [60] have estimated the risk 
of PML as 1 per 1,000 patients treated for an average of 
17.9 months (95% confidence interval 0.2–2.8 per 1,000), 
but this estimate is based on assumptions that may not be 
true. For example, if concomitant IFN-  therapy predis-
poses to PML, the risk for patients on natalizumab mono-
therapy will probably be much lower and possibly nonex-
istent. By contrast, if this complication can occur with 
natalizumab alone, the risk will possibly increase with 
higher exposure time to therapy so that the ultimate risk 
to patients (expected to be on treatment for many years) 
could be substantially greater.
 In view of the lacking evidence for an additional ben-
eficial effect of the use of a combined therapy of natali-
zumab with IFN – or with any other immune suppressive 
agent – such a combination is not recommended at pres-
ent.
  4 -Integrins exert additional functions in hematopoi-
esis and mucosal immunity. Thus, natalizumab might 
block other relevant biological events unrelated to T cell 
migration. In this context, it is interesting to note that in 
EAE, blocking   4 -integrins is more effective than block-
ing VCAM-1, and that an antibody that binds   4 -integ-
rins but does not block   4 -integrin-mediated lymphocyte 
homing  [61] can nevertheless interfere with EAE devel-
opment in the mouse  [25] .
 According to current Food and Drug Administration 
and European Medicines Agency recommendations, it is 
anticipated that the majority of patients treated with na-
talizumab in the near future will be those who failed to 
tolerate or more likely failed to respond adequately to 
IFN-  or glatiramer acetate. Naive patients will only be 
considered for treatment with natalizumab if they pre-
sent with unusually high disease activity as defined by 
relapses and gadolinium-enhancing lesions in MRI.
 Chronic inhibition of   4 -integrins has shown a great 
therapeutic potential in relapsing forms of MS but could 
have undesired effects which at present are not predict-
able. Only further thorough evaluation of MS patients 
under long-term treatment with natalizumab will allow 
for a better assessment of its benefit-risk ratio.
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